Therefore, combination of anti‐IL‐36γ with the traditional treatments may improve the efficacy of chemo‐, radio‐, or immune‐therapies and overcome the drug resistance for NSCLC patients. The gene discussed is IL36G; the disease is non-small cell lung carcinoma.